Skip to main content
. 2019 Jun 6;14(6):e0217964. doi: 10.1371/journal.pone.0217964

Fig 1. Incremental costs (horizontal axis) and QALYs (vertical axis) for treating F2-F4 fibrosis with DAAs in India compared to no treatment for various reinfection rates.

Fig 1